<DOC>
	<DOCNO>NCT00798213</DOCNO>
	<brief_summary>Participants acute myelogenous leukemia ( AML ) randomize SCH 727965 gemtuzumab ozogamicin . All participant acute lymphoblastic leukemia ( ALL ) receive SCH 727965 . Part 1 study determine activity SCH 727965 treatment participant AML participant ALL . Part 2 study determine activity SCH 727965 treatment participant AML experience disease progression standard treatment gemtuzumab ozogamicin Part 1 .</brief_summary>
	<brief_title>SCH 727965 Patients With Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia ( P04717AM2 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>For participant AML : Age &gt; =60 year , either sex , race . Diagnosis CD33positive AML World Health Organization criterion . Must first second relapse , primary refractory refractory disease first salvage , consider candidate transplant . Acute promyelocytic leukemia relapse follow treatment trans retinoic acid ( tretinoin ) arsenic trioxidebased therapy eligible . For participant ALL : Age &gt; =18 year , either sex , race . Diagnosis ALL World Health Organization criterion . Must first second relapse , primary refractory refractory disease first salvage , consider candidate potentially curative therapy . Eastern Cooperative Oncology group performance status 0 1 . Adequate hematologic , renal , hepatic organ function laboratory parameter . Receiving treatment hydroxyurea leukapheresis reduce elevate white blood cell count &lt; =30 x 10^9 eligible , provide hydroxyurea leukapheresis discontinue least 24 hour initiation study drug . Known central nervous system leukemia . Previous hematopoietic stem cell transplantation . Previous treatment SCH 727965 cyclindependent kinase inhibitor . For AML , previous treatment gemtuzumab ozogamicin . Known HIV infection . Known active hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>